Frontiers in CAR-T Cell Therapy: Current Applications and Future Directions
Frontiers in Science and Engineering, (2024), Vol.4, No.10, pp.74-80
Published: October 22, 2024
DOI: 10.54691/66356c27
Abstract
CAR-T cell therapy, an ascending star in the immunotherapy landscape, harnesses the patient's innate immune defenses to confront cancer and a spectrum of hematologic disorders, while also exhibiting promising avenues for application in other maladies. This comprehensive review delves into the fundamental mechanisms of CAR-T cell therapy, the evolution and design strategies of successive generations of CAR-T cells, as well as the advancements and clinical implementations achieved in treating a diverse array of diseases.
Keywords:
CAR-T cell therapy, immunotherapy, chimeric antigen receptor, hematologic malignancies, solid tumors, autoimmune diseases, cytokine release syndrome, neurotoxicity, antigen escape, tumor microenvironment.
APA Citation:
Yizhou Huang (2024). Frontiers in CAR-T Cell Therapy: Current Applications and Future Directions. Frontiers in Science and Engineering, 4(10), 74-80. https://doi.org/10.54691/66356c27
References
- Jayaraman, J., et al., CAR-T design: Elements and their synergistic function. EBioMedicine, 2020. 58: p. 102931.
- Mohanty, R., et al., CAR T cell therapy: A new era for cancer treatment (Review). Oncology Reports, 2019.
- Li, C., et al., Treatment of multiple myeloma: What is the impact on T-cell function? Therapeutic Advances in Hematology, 2024. 15.
- Munshi, N.C., et al., Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, 2021. 384(8): p. 705-716.
- Pang, Y. and N. Ghosh, Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma. Frontiers in Oncology, 2024. 14.
- Shi, D., et al., Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clinical Cancer Research, 2020. 26(15): p. 3979-3989.
- Cutri-French, C., et al., CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now? Diagnostics (Basel), 2024. 14(8).
- Lahiri, A., et al., Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer, 2023. 22(1).
- Chen, L., et al., <scp>CAR‐T</scp> cell therapy for lung cancer: Potential and perspective. Thoracic Cancer, 2022. 13(7): p. 889-899.
- Zhang, X., et al., GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies. Frontiers in Immunology, 2023. 14.
- Chang, Y., & Tian, J. (2024, March 8). New breakthroughs in CAR-T treatment for myasthenia gravis [Newspaper article]. Health News, p. 002.
- Mackensen, A., et al., Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med, 2022. 28(10): p. 2124-2132.
- Kong, D., et al., Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center. Front Immunol, 2023. 14: p. 1200748.
- Seif, M., H. Einsele, and J. Loffler, CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases. Front Immunol, 2019. 10: p. 2711.